Delivery Order SPE2DB20D3103-SPE2DB25FQ1Q6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Tafinlar 75 mg capsules (120 count) valued at $8,896.41, with an ultimate completion date of September 22, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price pricing and is being performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tafinlar 75 mg capsules (120-count units) under a firm fixed-price contract valued at $8,896.41. The award was issued on August 5, 2025, with an ultimate completion date of August 26, 2025. This non-set-aside competitive award represents a continuation of AmerisourceBergen's critical role as a pharmaceutical distributor supporting federal medical procurement needs, particularly for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,836.26 to AmerisourceBergen Drug Corp for the supply of Tafinlar 50 mg capsules (120 count) under a firm fixed price contract. The order was competitively awarded without set-aside designation and is scheduled for completion by August 20, 2025. AmerisourceBergen will perform this work from its corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Tafinlar 75 mg capsules (120 count) with a ceiling value of $8,896.41. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The order is scheduled for completion by September 12, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Tafinlar 50 mg capsules (120 count) at a firm fixed price of $13,836.26. This is a non-set-aside contract with an ultimate completion date of September 12, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a purchase under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $8,896.41 to AmerisourceBergen Drug Corp for the supply of Tafinlar 75 mg capsules (120 count) on August 29, 2025, with an ultimate completion date of September 22, 2025. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in...
- The U.S. Defense Logistics Agency (DLA) awarded a $8,139.33 firm-fixed-price delivery order to AmerisourceBergen Drug Corporation for the supply of 4,565,810 units of the pharmaceutical product Tafinlar 75 mg capsules. The order has an ultimate completion date of October 4, 2024. AmerisourceBergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) valued up to $999,999,999 with the DLA Troop Support Medical through December 2025 for delivering a range...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Tafinlar 50 mg capsules (120-count units) with a ceiling value of $13,836.26. This firm fixed-price delivery order, with an ultimate completion date of September 24, 2025, represents a competitively awarded, non-set-aside contract with no small business preferences applied. The work is being performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $13,836.26 to AmerisourceBergen Drug Corp for the supply of Tafinlar 50 mg capsules (120 count) on September 4, 2025, with an ultimate completion date of September 25, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tafinlar (dabrafenib) is a targeted cancer therapy used primarily for melanoma...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,792.82 firm fixed-price contract is for the supply of 4,568,120,296 units of the prescription medication Tafinlar 75 mg capsule. The contract has a period of performance through May 23, 2025. This award is not associated with a set-aside program and is part of a larger $999,999,999.00 Indefinite Delivery Contract...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ1Q6Delivery Order
The Defense Logistics Agency awarded a $8.9K delivery order to AmerisourceBergen Drug Corp for the supply of Tafinlar 75 mg capsules (120-count units) under a firm fixed-price contract. The award, issued on September 4, 2025, with an ultimate completion date of September 25, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location and serves as a critical pharmaceutical distributor for federal medical procurement needs across military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. This prime vendor agreement enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. The current award for Tafinlar, a melanoma treatment medication, exemplifies the company's role in fulfilling specialized pharmaceutical requirements across the federal healthcare supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 9/4/25 |